I was following a string on Twitter and read about someone

New Post Public Reply Private Reply Replies (1) Message Board
Enjay
745
I was following a string on Twitter and read about someone whose brain fog had been helped by a study at Yale. The most interesting part to me was that the medicines they are using are already approved for other indications. If you or anyone you know is suffering from brain fog, I encourage you to read the story. I'll post some excerpts and the link below. (I still regret that we are not pursuing LC. From the anecdotal reports I heard, many in the LC trial were helped by Leronlimab. Sure would like to know why we dropped that.)



Potential New Treatment for “Brain Fog” in Long COVID Patients

Individuals with long COVID, sometimes referred to as “long-haulers,” experience symptoms that may persist for weeks, months, or even years after their acute viral infection. While symptoms vary widely, a common complaint among patients is “brain fog”—a colloquial term for significant, persistent cognitive deficits, with consistent impairment of executive functioning and working memory. Long-haulers may experience a lack of mental clarity, poor focus and concentration, memory problems, difficulty with multi-tasking, and more. Brain fog can be debilitating, but there currently are no treatment options that are approved for the condition.

While the number of patients they studied is too small for their results to be definitive, Yale researchers—using their extensive experience with two existing medications—have published initial evidence that those drugs, given together, can mitigate or even eliminate brain fog.

Guanfacine, developed in the lab of Amy Arnsten, PhD, Albert E. Kent Professor of Neuroscience and professor of psychology, was approved by the Food and Drug Administration (FDA) for the treatment of ADHD in 2009, but clinicians have also used it extensively off-label for other prefrontal cortical disorders such as traumatic brain injury (TBI) and PTSD. Now, Arnsten has joined forces with Arman Fesharaki-Zadeh, MD, PhD, assistant professor of psychiatry and of neurology, who has been treating long COVID patients with a combination of guanfacine and N-acetylcysteine (NAC), an anti-oxidant also used for the treatment of TBI. The combined therapy, they found, was successful in relieving brain fog for their small cohort of patients. And while larger, placebo-controlled clinical trials will be needed to establish these drugs as a bona fide treatment for post-COVID-19 neurocognitive deficits, they say patients can obtain them now if their doctors wish to prescribe them.

“There’s a paucity of treatment out there for long COVID brain fog, so when I kept seeing the benefits of this treatment in patients, I felt a sense of urgency to disseminate this information,” says Fesharaki-Zadeh. “You don’t need to wait to be part of a research trial. You can ask your physician—these drugs are affordable and widely available.” Because they are FDA-approved and have been used for years, their safety for patients is established.

The researchers published their case study in Neuroimmunology Reports on November 25.

https://medicine.yale.edu/news-article/potent...-patients/

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 332

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 117

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 238

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 46

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 344

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 22

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 15

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Willis Towers Watson's P/E Ratio Dynamics

Updated Category News Views 190

Current Stock Overview In today's market, Willis Towers Watson Inc. stock is priced at $325.59, reflecting a slight increase of 0.02%. Over the past month, the stock has risen by 5.11% and has shown a notable yearly increase of 17.73%. Such performance has led to optimism among long-term shareholders, although many are considering the price-to-earnings (P/E) ratio as a...

Continue Reading
Sterling Infrastructure to Engage Investors at Key Conferences

Updated Category News Views 79

Sterling Infrastructure to Engage Investors at Key Conferences Sterling Infrastructure, Inc. (NASDAQ: STRL) is making strides in connecting with investors by participating in several upcoming investor conferences. These events present a fantastic opportunity for the company's management to share insights and updates regarding their ongoing projects and strategic...

Continue Reading
Rivian's $5 Billion Factory Plans and Market Dynamics in EV

Updated Category News Views 224

Exciting Developments in the EV Industry The electric vehicle (EV) space has witnessed some thrilling changes recently. Major companies like Rivian, Tesla, and BYD are at the forefront of this industry evolution. This article will recap some standout events that have kept the tech world buzzing. Rivian's Ambitious Factory Plans Construction Begins on a $5 Billion Facility...

Continue Reading
Berry Global Group Secures $800 Million in Senior Notes

Updated Category News Views 273

Berry Global Group's Strategic $800 Million Notes Issuance Berry Global Group, Inc. (NYSE: BERY) has taken a significant step in bolstering its financial structure with the announcement of the issuance of $800 million in senior secured notes due in 2031. The notes, which carry an attractive interest rate of 7.250% per annum, reflect the company's ambition and strategic...

Continue Reading
AdaptHealth Corp. Welcomes Russell Schuster as CCO for Growth

Updated Category News Views 108

Russell Schuster Joins AdaptHealth as Chief Commercial Officer AdaptHealth Corp. (NASDAQ: AHCO), a prominent provider of patient-centered healthcare-at-home solutions, has made a significant addition to its leadership team by appointing Russell Schuster as Chief Commercial Officer. His role is effective immediately and brings a wealth of expertise aimed at enhancing the...

Continue Reading